A competitive ligand-binding assay for the detection of neutralizing antibodies against dostarlimab (TSR-042)
Abstract Dostarlimab is a humanized anti–PD-1 monoclonal antibody. Dostarlimab (JEMPERLI; TSR-042) was recently approved in the USA and in the EU. The presence of neutralizing antibodies (NAbs) is a cause for concern because they block the therapeutic function of the antibody and reduce drug efficac...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
SpringerOpen
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9cc562b825a24dee8a7fce5d389aa00c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|